Publication Author: Goodman SG
Filter by Author:
Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.
Reijnders E, Bossuyt P, Jukema JW, Ruhaak LR, Romijn F, Szarek M, Trompet S, Bhatt D, Bittner V, Diaz R, Fazio S, Stevanovic I, Goodman S, Harrington R, White H, Steg PG, Schwartz G, Cobbaert C.
Cardiovascular-related hospital visits amongst oncology patients receiving immune checkpoint inhibitors: A population-based cohort study.
Dai WF, Habbous S, Yan A, Abdel-Qadir H, Goodman SG, Chan KKW.
Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI.
Fioretti F, Butler J, Udell JA, Schuyler Jones W, Petrie MC, Harrington J, Mattheus M, Bauersachs J, Bayes-Genis A, Goodman SG, Gasior T, Januzzi JL, Lopes RD, Ponikowski P, Rossello X, Schou M, van der Meer P, Vinereanu D, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF, Anker SD.
Real-world effectiveness of early revascularization in stable coronary artery disease with moderate or severe ischemia.
Gerodias FJ, Iwanochko RM, Austin PC, Wang X, Džavík V, Goodman SG, Udell JA, Ouzounian M, Ross HJ, Godoy LC, Amad H, Husain M, Lee DS.
ipoprotein(a) identifies patients with acute coronary syndromes who derive cardiovascular benefit from alirocumab, particularly for limb events.
Ray KK, Szarek M, Bhatt DL, Bittner VA, Fazio S, Goodman SG, Harrington RA, Jukema JW, White HD, Steg PG, Schwartz GG.
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial.
Patel SM, Giugliano RP, Morrow DA, Goodrich EL, Murphy SA, Hug B, Parkar S, Chen SA, Goodman SG, Joung B, Kiss RG, Wojakowski W, Weitz JI, Bloomfield D, Sabatine MS, Ruff CT.
Effectiveness of the GRACE risk score according to troponin elevation in patients admitted with non-ST elevation acute coronary syndrome: a post hoc analysis of the UKGRIS parallel group cluster randomised controlled trial.
Gale CP, Stocken D, Nadarajah R, Aktaa S, Reynolds C, Gilberts R, Brieger DB, Carruthers K, Chew DP, Goodman S, Fernandez C, Sharples L, Yan AT, Fox KAA.
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.
Al Said S, Patel SM, Giugliano RP, Morrow DA, Goodrich EL, Murphy SA, Hug B, Parkar S, Chen SA, Goodman SG, Joung B, Kiss RG, Wojakowski W, Weitz JI, Bloomfield D, Sabatine MS, Ruff CT.
Long-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis From AZALEA-TIMI 71.
Patel SM, Giugliano RP, Morrow DA, Parkar S, Shapiro H, Hug B, Kuder JF, Goodrich EL, Chen SA, Goodman SG, Joung B, Kiss RG, Wojakowski W, Weitz JI, Murphy SA, Wiviott SD, Bloomfield D, Sabatine MS, Ruff CT.
Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEART
Wade Thompson, Brendan Wong, Atul Sivaswamy, Laura Ferreira-Legere, Douglas S. Lee, Husam Abdel-Qadir, Dennis T. Ko, Alanna Weisman, Sheldon Tobe, Cynthia A. Jackevicius, Shaun G. Goodman, Michael E. Farkouh, Jacob A. Udell
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels.
Rikken SAOF, Gibson CM, Bahit MC, Duffy D, Chi G, Korjian S, Mohammadnia N, White H, Anschuetz G, Kingwell BA, Ophuis TO, Nicolau JC, Lopes RD, Lewis BS, El Messaoudi S, Vinereanu D, Ten Berg JM, Goodman SG, Bode C, Steg PG, Libby P, Bainey KR, van 't Hof AWJ, Ridker PM, Mahaffey KW, Nicholls SJ, Mehran R, Harrington RA, Cornel JH; AEGIS-II Committees and Investigators.
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES.
Steg PG, Szarek M, Jukema JW, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators.
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism.
Capodanno D, Alexander JH, Bahit MC, Eikelboom JW, Gibson CM, Goodman SG, Kunadian V, Lip GYH, Lopes RD, Mehran R, Mehta SR, Patel MR, Piccini JP, Rao SV, Ruff CT, Steg PG, Weitz JI, Angiolillo DJ.
Apixaban Dose in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Fudim M, Lopes RD, Wojdyla DM, Mehran R, Khan MS, Granger CB, Goodman SG, Aronson R, Windecker S, Alexander JH.
Prognostic Implications of Machine Learning Algorithm-Supported Diagnostic Classification of Myocardial Injury Using the Fourth Universal Definition of Myocardial Infarction.
Lambrakis K, Khan E, Liao Z, Gerlach J, Nelson AJ, Goodman SG, Briffa T, Cullen L, Verjans J, Chew DP.
Blood Transfusion in Patients With Acute Myocardial Infarction, Anemia, and Heart Failure: Lessons From MINT.
Goldsweig AM, Kostis WJ, Herbert BM, Bouleti C, Potter BJ, Strom JB, Benatar J, Huynh T, Vallurupalli S, Figueiredo EL, Abbott JD, Cooper HA, DeFilippis AP, Fergusson DA, Goodman SG, Hébert PC, Lopes RD, Rao SV, Simon T, Carson JL, Brooks MM, Alexander JH; MINT Investigators.
Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial.
Alexander JH, Lydon EJ, Piccini JP, Viethen T, Oldgren J, Goodman SG, Steffel J, Russo AM, van Gelder IC, Ferdinand KC, Lopes RD, Mundl H, Benczur B, Gómez-Doblas JJ, Glikson M, Goudev A, Grove EL, Halvorsen S, Kiviniemi T, Martin AC, Sandhu RK, Vinereanu D, Rockhold FW, Caso V, Coppolecchia R, Patel MR.
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial.
Schwartz GG, Szarek M, Jukema JW, Cobbaert CM, Reijnders E, Bittner VA, Schwertfeger M, Bhatt DL, Fazio S, Garon G, Goodman SG, Harrington RA, White HD, Steg PG.
Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS.
Tannu M, Lopes RD, Wojdyla DM, Goodman SG, Aronson R, Mehran R, Granger CB, Windecker S, Alexander JH, Jones WS.
Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome.
Schwartz GG, Szarek M, Reijnders E, Jukema JW, Bhatt DL, Bittner VA, Fazio S, Garon G, Goodman SG, Harrington RA, White HD, Ruhaak LR, Stevanovic I, Cobbaert CM, Steg PG.
